AGP Executive Report
Last update: 6 hours agoPatient Access: South Africa’s reported freeze on new Section 21 approvals has left some patients with epilepsy and serious neurological conditions worried about losing treatment. Advocates say compliant patients are caught up in efforts to curb operator abuse. U.S. Hemp Rules: Hemp businesses are bracing for looming federal THC restrictions, while the FDA is nine months late issuing legally required guidance, adding uncertainty for sellers and farmers. Health & Safety: Cannabis use was linked to higher mortality among people with alcohol-associated hepatitis. Separate data found cannabis in records for 84% of teens receiving emergency care for substance-related cases; the finding does not establish cause. Medical R&D: Jammu researchers say a medicinal cannabis project aims to develop export-quality medicines for cancer and epilepsy. UK-based Grow Group, which supplies prescribed cannabis medicines in several countries, secured new financing and a debt restructuring.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
